Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Completed · Phase 2
Conditions studied: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation therapy. PURPOSE: Phase II trial to study the effectiveness of amifostine plus chemotherapy and radiation therapy in treating patients who have limited-stage small cell lung cancer.
Key facts
- Study ID
- NCT00004176
- Run by
- Washington University School of Medicine
- People needed
- 34
- Starts
- 1998-10-01
- Expected to finish
- 2001-02-01
- Last updated by the study team
- 2013-05-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Rocky Mountain Cancer Center — Denver, Colorado, United States
- Washington University Barnard Cancer Center — St Louis, Missouri, United States
- Lineberger Comprehensive Cancer Center, UNC — Chapel Hill, North Carolina, United States
- University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.